2395.T
Latest Trade
625.00JPYChange
8.00(+1.30%)Volume
136,200Today's Range
-
628.0052 Week Range
-
980.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 617.00 |
|---|---|
Open | 614.00 |
Volume | 136,200 |
3M AVG Volume | 5.23 |
Today's High | 628.00 |
Today's Low | 614.00 |
52 Week High | 980.00 |
52 Week Low | 481.00 |
Shares Out (MIL) | 41.63 |
Market Cap (MIL) | 25,687.19 |
Forward P/E | -- |
Dividend (Yield %) | 0.49 |
Shin Nippon Biomedical Laboratories to sell unit for 1 bln yen
Shin Nippon Biomedical Laboratories says 2016 dividend payment date is Aug. 16
Shin Nippon Biomedical Laboratories to cut stake in SNBL Clinical Pharmacology Center, Inc. to 67.4 pct from 100 pct
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Industry
Biotechnology & Drugs
Executive Leadership
Ryoichi Nagata
Chairman of the Board, President, Group Chief Executive Officer, Chairman of Subsidiary, Representative Director
Koichiro Fukuzaki
Vice Chairman of the Board
Takeshi Yamakawa
Chief Executive Officer of Subsidiary, Director
Ken Takanashi
Chief Operating Officer, Vice President, Representative Director
Shuichi Kanazashi
Managing Director, President of TR Business Company
Price To Earnings (TTM) | 16.86 |
|---|---|
Price To Sales (TTM) | 1.75 |
Price To Book (MRQ) | 1.07 |
Price To Cash Flow (TTM) | 9.05 |
Total Debt To Equity (MRQ) | 64.42 |
LT Debt To Equity (MRQ) | 16.99 |
Return on Investment (TTM) | 4.61 |
Return on Equity (TTM) | 2.96 |
* Says the co to cut stake in the U.S.-based unit, SNBL Clinical Pharmacology Center, Inc., to 67.4 percent from 100 percent
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.